<!doctype html>
<html lang="en"><head>
<meta charset="utf-8"/><meta name="viewport" content="width=device-width,initial-scale=1"/>
<link rel="stylesheet" href="/newsletter/style.css"/>
<title>WHO adds GLP-1RAs to essential medicines list — Newsletter</title>
</head><body>
<div class="container">
  <div class="header">
    <h1 style="margin:0;font-size:28px">Newsletter</h1>
    <a class="btn" href="/newsletter/">Home</a>
  </div>
  <div class="card">
    <h2 style="margin-top:0">WHO adds GLP-1RAs to essential medicines list</h2>
    <div class="badge">2025-09-08T17:59:13+00:00</div>
    <ul>
      <li>This has led analysts at GlobalData, parent company of Pharmaceutical Technology, to forecast that Saxenda will make just $135m in 2031 – down 91% from the $1.5bn sales seen at its peak in 2022.</li>
<li>Meanwhile, Trulicity also offers only a small price reduction, being sold at $987 instead of the $1079.77 charge for Mounjaro.</li>
<li>Generics to improve GLP-1RA accessibility The August 2025 US approval of Teva Pharmaceutical’s generic Saxenda has left Novo Nordisk’s version vulnerable to competition.</li>
<li>However, WHO raised concerns about the costs of both semaglutide and tirzepatide, which come with a hefty price tag of between $997 and $1349 for a one-month prescription in the US, which the agency warns could complicat</li>
<li>The World Health Organisation (WHO) has updated its model list of essential medicines (EML) to include four key obesity and type 2 diabetes (T2D) drugs.</li>
<li>The United Nations (UN) agency has added the glucagon-like peptide-1 receptor agonists (GLP-1RAs) and dual GLP-1/glucose-dependent insulinotropic polypeptide (GIP) receptor agonists to the EML following a review from the</li>
<li>Saxenda is currently very similar in price to its more efficacious successor, semaglutide.</li>
    </ul>
    <p>
      <a class="btn" href="https://twitter.com/intent/tweet?text=WHO adds GLP-1RAs to essential medicines list\n• This has led analysts at GlobalData, parent company of Pharmaceutical Technology, to forecast that Saxenda will make just $135m in 2031 – down 91% from the $1.5bn sales seen at its peak in 2022.\n• Meanwhile, Trulicity also offers only a small price reduction, being sold at $987 instead of the $1079.77 charge for Mounjaro.\n• Generics to improve GLP-1RA accessibility The August 2025 US approval of Teva Pharmaceutical’s generic Saxenda has left Novo Nordisk’s version vulnerable to competition.\n• However, WHO raised concerns about the costs of both semaglutide and tirzepatide, which come with a hefty price tag of between $997 and $1349 for a one-month prescription in the US, which the agency warns could complicat\n• The World Health Organisation (WHO) has updated its model list of essential medicines (EML) to include four key obesity and type 2 diabetes (T2D) drugs.\n• The United Nations (UN) agency has added the glucagon-like peptide-1 receptor agonists (GLP-1RAs) and dual GLP-1/glucose-dependent insulinotropic polypeptide (GIP) receptor agonists to the EML following a review from the\n• Saxenda is currently very similar in price to its more efficacious successor, semaglutide." target="_blank" rel="noopener">Tweet bullets</a>
      &nbsp;&nbsp;
      <a href="https://finance.yahoo.com/m/bb4b1ca7-94ec-368e-9014-307f68cd1bcb/who-adds-glp-1ras-to.html" target="_blank" rel="noopener nofollow">finance.yahoo.com</a>
    </p>
  </div>
  <div class="footer">Built from digest_5bullets.md</div>
</div>
</body></html>